Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...

Drugmaker Eli Lilly is rolling out a new model to make it easier for employers to provide access to its GLP-1 drugs for weight management. Lilly said in an announcement that the model is built on ...

Silicon Valley’s giants crowd the list of the world’s most valuable companies, but drugmaker Eli Lilly is hot on their heels. The company topped a market capitalization of $1 trillion on Friday, ...

Local leaders are excited for the largest initial investment in state history, saying it will boost the local economy and ...

Nov. 21 (UPI) --Healthcare giant Eli Lilly on Friday became the first global healthcare company to hit $1 trillion in value. The Indiana-based company hit the $1 trillion market capitalization ...

Eli Lilly just agreed to lower the price of its blockbuster GLP-1 weight loss drug. More than half of the company's revenue comes from just two weight loss drugs. Wall Street may be pricing in too ...

Eli Lilly (LLY) remains a core holding at 7% of NAV, but I have trimmed my position by 50% after a 38.8% price return since purchasing earlier in 2025. I have taken the proceeds and increased my MP ...

Eli Lilly delivered 54% revenue growth in Q3 2025, raised full-year guidance, and remains a defensive haven amid market volatility. LLY's obesity and diabetes franchise, led by Zepbound, Mounjaro, and ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly ...

Eli Lilly and Co (NYSE: LLY) shares are trading higher on Friday. The company plans to start selling its obesity drug through a new approach aimed at expanding access. What To Know: Eli Lilly is ...